Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach' - 2Toyota Reports 2.3% Sales Drop as China Weakness Deepens
- 3Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- 4Astronomers detect rare 'free floating' exoplanet 10,000 light-years from Earth
- 5Bond Girl Ursula Andress’ $23 Million Fortune Once ‘Fraudulently Misappropriated’ Was Allegedly Found
- Genome study reveals milestone in history of cat domestication
- A NASA spacecraft orbiting Mars may be dead
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 7 Popular Vacation destinations In China
- Vote In favor of Your Favored Sort Of Dress
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- Common ADHD medication prescribed in childhood may protect against risk of psychosis
- Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- Explainer-What will change with the US reclassification of marijuana?
